NASDAQ:IVVD Invivyd (IVVD) Stock Forecast, Price & News $1.64 -0.02 (-1.20%) (As of 10:21 AM ET) Add Compare Share Share Today's Range$1.60▼$1.6650-Day Range$1.35▼$1.8952-Week Range$0.98▼$4.09Volume7,684 shsAverage Volume280,566 shsMarket Capitalization$180.01 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Invivyd MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside82.9% Upside$3.00 Price TargetShort InterestHealthy4.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.87) to ($0.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector619th out of 964 stocksBiological Products, Except Diagnostic Industry95th out of 160 stocks 3.0 Analyst's Opinion Consensus RatingInvivyd has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Invivyd has a forecasted upside of 82.9% from its current price of $1.64.Amount of Analyst CoverageInvivyd has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.88% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Invivyd has recently decreased by 18.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldInvivyd does not currently pay a dividend.Dividend GrowthInvivyd does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IVVD. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 1 people have searched for IVVD on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows1 people have added Invivyd to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invivyd insiders have not sold or bought any company stock.Percentage Held by Insiders19.10% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.94% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Invivyd are expected to grow in the coming year, from ($1.87) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invivyd is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invivyd is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvivyd has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Invivyd (NASDAQ:IVVD) StockInvivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Read More IVVD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IVVD Stock News HeadlinesSeptember 11, 2023 | benzinga.comInvivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19September 6, 2023 | finance.yahoo.comInvivyd to Participate in Upcoming Investor ConferencesSeptember 22, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>September 5, 2023 | seekingalpha.comInvivyd gets new finance chiefSeptember 5, 2023 | markets.businessinsider.comInvivyd Appoints William Duke As New CFOSeptember 5, 2023 | finance.yahoo.comInvivyd Appoints William Duke as Chief Financial OfficerAugust 29, 2023 | finance.yahoo.comInvivyd (IVVD) Stock Rises 18% in 3 Months: Here's WhyAugust 15, 2023 | finance.yahoo.comInvivyd, Inc. (NASDAQ:IVVD) Q2 2023 Earnings Call TranscriptSeptember 22, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>August 14, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Invivyd (IVVD)August 10, 2023 | finance.yahoo.comInvivyd Reports Second Quarter 2023 Financial Results and Business HighlightsAugust 3, 2023 | finance.yahoo.comInvivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business HighlightsJuly 28, 2023 | finance.yahoo.comInvivyd Announces Appointment of Sara Cotter to Board Of DirectorsJuly 22, 2023 | businesswire.comINVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGIJuly 17, 2023 | finance.yahoo.comInvivyd's COVID-19 Antibody Shows Favorable Safety, Tolerability Profile For Immunocompromised PeopleJuly 17, 2023 | finance.yahoo.comInvivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised PeopleJune 26, 2023 | tmcnet.comInvivyd Announces General Alignment with FDA on PathwayJune 23, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About InvivydJune 22, 2023 | finance.yahoo.comInvivyd Says Investigational Antibody Shows Potential To Prevent Symptomatic COVID-19May 23, 2023 | finance.yahoo.comIs Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?May 12, 2023 | marketwatch.comInvivyd Reports First Quarter 2023 Financial Results and Business HighlightsMay 11, 2023 | msn.comInvivyd: Q1 Earnings InsightsMay 11, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Esperion (ESPR), Invivyd (IVVD)May 10, 2023 | msn.com4IVVD : Earnings Preview: InvivydMay 4, 2023 | finance.yahoo.comInvivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business HighlightsApril 25, 2023 | benzinga.comInvivyd to Participate at H.C. Wainwright's BioConnect Investor ConferenceApril 25, 2023 | finance.yahoo.comInvivyd to Participate at H.C. Wainwright’s BioConnect Investor ConferenceSee More Headlines Receive IVVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter. Email Address IVVD Company Calendar Last Earnings8/10/2023Today9/21/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IVVD CUSIPN/A CIK1832038 Webadagiotx.com Phone781-819-0080FaxN/AEmployees84Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+80.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-241,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.25% Return on Assets-47.56% Debt Debt-to-Equity RatioN/A Current Ratio9.54 Quick Ratio9.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.27 per share Price / Book0.51Miscellaneous Outstanding Shares109,756,000Free Float88,793,000Market Cap$182.19 million OptionableOptionable Beta-0.12 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. David Hering M.B.A. (Age 47)CEO & Director Comp: $932.5kMs. Jill Andersen J.D. (Age 50)Chief Legal Officer & Corp. Sec. Comp: $619.33kMr. William E. Duke Jr. (Age 51)M.B.A., Chief Financial Officer Mr. Jeremy Gowler (Age 46)Chief Operating Officer & Chief Commercial Officer Ms. Stacy Price M.S. (Age 54)Chief Technology & Manufacturing Officer Dr. Robert D. Allen Ph.D.Chief Scientific OfficerMs. Julie Green M.B.A.Sr. VP of HRDr. Peter C. Schmidt M.D. (Age 42)M.S., M.Sc., Chief Medical Officer Ms. Heidi Spurling M.S.VP of Strategy & Operations and Chief of Staff to the CEOMore ExecutivesKey CompetitorsTaysha Gene TherapiesNASDAQ:TSHAFennec PharmaceuticalsNASDAQ:FENCInnate PharmaNASDAQ:IPHAMesoblastNASDAQ:MESOTenaya TherapeuticsNASDAQ:TNYAView All CompetitorsInstitutional OwnershipRBF Capital LLCBought 203,683 shares on 8/15/2023Ownership: 0.186%Y Intercept Hong Kong LtdBought 111,936 shares on 8/15/2023Ownership: 0.102%Goldman Sachs Group Inc.Sold 38,555 shares on 8/15/2023Ownership: 0.040%Citadel Advisors LLCSold 300 shares on 8/15/2023Ownership: 0.000%Shay Capital LLCBought 41,859 shares on 8/14/2023Ownership: 0.080%View All Institutional Transactions IVVD Stock - Frequently Asked Questions Should I buy or sell Invivyd stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invivyd in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" IVVD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IVVD, but not buy additional shares or sell existing shares. View IVVD analyst ratings or view top-rated stocks. What is Invivyd's stock price forecast for 2023? 2 Wall Street analysts have issued twelve-month target prices for Invivyd's stock. Their IVVD share price forecasts range from $1.00 to $5.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 80.7% from the stock's current price. View analysts price targets for IVVD or view top-rated stocks among Wall Street analysts. How have IVVD shares performed in 2023? Invivyd's stock was trading at $1.50 at the start of the year. Since then, IVVD shares have increased by 10.7% and is now trading at $1.66. View the best growth stocks for 2023 here. Are investors shorting Invivyd? Invivyd saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 1,940,000 shares, a drop of 18.1% from the August 15th total of 2,370,000 shares. Based on an average daily volume of 387,900 shares, the short-interest ratio is presently 5.0 days. Currently, 4.9% of the shares of the stock are short sold. View Invivyd's Short Interest. When is Invivyd's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our IVVD earnings forecast. How were Invivyd's earnings last quarter? Invivyd, Inc. (NASDAQ:IVVD) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.06. What ETF holds Invivyd's stock ? ETFMG Treatments Testing and Advancements ETF holds 30,909 shares of IVVD stock, representing 0.32% of its portfolio. What is Invivyd's stock symbol? Invivyd trades on the NASDAQ under the ticker symbol "IVVD." Who are Invivyd's major shareholders? Invivyd's stock is owned by a variety of institutional and retail investors. Top institutional investors include 683 Capital Management LLC (3.64%), Citigroup Inc. (2.13%), BlackRock Inc. (1.20%), Geode Capital Management LLC (0.47%), Charles Schwab Investment Management Inc. (0.26%) and RBF Capital LLC (0.19%). How do I buy shares of Invivyd? Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Invivyd's stock price today? One share of IVVD stock can currently be purchased for approximately $1.66. How much money does Invivyd make? Invivyd (NASDAQ:IVVD) has a market capitalization of $182.19 million. The company earns $-241,320,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. How can I contact Invivyd? Invivyd's mailing address is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. The official website for the company is adagiotx.com. The company can be reached via phone at 781-819-0080 or via email at investors@adagiotx.com. This page (NASDAQ:IVVD) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.